- Author:
Jung Min SUH
1
;
Sang Goo LEE
;
Keon Hee YOO
;
Ki Woong SUNG
;
Hong Hoe KOO
;
Ju Youn KIM
;
Eun Joo CHO
;
Suk Koo LEE
;
Jhingook KIM
;
Do Hoon LIM
Author Information
- Publication Type:Original Article
- Keywords: Neuroblastoma; Prognosis
- MeSH: Aged; Disease-Free Survival; Follow-Up Studies; Humans; Myocarditis; Neuroblastoma; Prognosis; Recurrence; Stem Cells
- From:Korean Journal of Pediatrics 2009;52(1):93-98
- CountryRepublic of Korea
- Language:Korean
- Abstract: PURPOSE: The purpose of this study was to evaluate the clinical characteristics and outcomes of patie nts with neuroblastoma aged less than 1 year. METHODS: From January 1997 to December 2007, 41 patients aged less than 1 year were diagnosed with neuroblastoma. Patients were divided into 3 risk groups according to the stage of the disease and N-myc amplification. Low-risk patients underwent surgery with (stage 2) or without (stage 1) short-term chemotherapy. Intermediate-risk patients underwent chemotherapy and surgery with or without local radiation therapy. High-risk patients underwent chemotherapy, surgery, radiation therapy, and high-dose chemotherapy/autologous stem cell rescue (HDCT/ASCR). RESULTS: While tumor relapse occurred in only 1 patient, 7 patients died of treatment-related toxicities. Causes of treatment-related death included infection during conventional chemotherapy in 5 patients and acute myocarditis during HDCT/ASCR in 2 patients. The overall 5-year survival (+/-standard error) and 5-year event-free survival (EFS) rates after diagnosis for all 41 patients were 82.8+/-5.9% and 80.0+/-6.3%, respectively, with a median follow-up of 58 (9-137) months. The 5-year EFS rates for low-risk, interme diate-risk, and high-risk patients were 100%, 68.4+/-10.8%, and 66.7+/-19.3%, respectively. CONCLUSION: Increased efforts to reduce infection-associated toxicity deaths during conventional chemotherapy are needed to further improve the survival of patients with neuroblastoma aged less than 1 year.